Antonio Augusto Lopes

List of Publications by Year
in descending order

83 papers	1,620 citations	304743 22 h-index	315739 38 g-index
88 all docs	88 docs citations	88 times ranked	1927 citing authors

#	Article	IF	Citations
1	A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 286-298.	1.7	215
2	Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. American Journal of Medicine, 2004, 116, 369-374.	1.5	120
3	Functional Classification of Pulmonary Hypertension in Children: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 280-285.	1.7	92
4	Altered endothelial function following the Fontan procedure. Cardiology in the Young, 2008, 18, 70-4.	0.8	76
5	Circulating von Willebrand Factor Antigen as a Predictor of Short-term Prognosis in Pulmonary Hypertension. Chest, 1998, 114, 1276-1282.	0.8	66
6	Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiology in the Young, 2009, 19, 431-435.	0.8	53
7	NKX2.5 mutations in patients with non-syndromic congenital heart disease. International Journal of Cardiology, 2010, 138, 261-265.	1.7	53
8	Cardiac Catheterization in Children with Pulmonary Hypertensive Vascular Disease: Consensus Statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. Pulmonary Circulation, 2016, 6, 118-125.	1.7	49
9	Repair of Congenital Heart Disease with Associated Pulmonary Hypertension in Children: What are the Minimal Investigative Procedures? Consensus Statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2014, 4, 330-341.	1.7	44
10	Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. American Heart Journal, 2000, 139, 618-623.	2.7	43
11	Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. American Journal of Medicine, 1998, 105, 21-26.	1.5	41
12	ALDH1A2 (RALDH2) genetic variation in human congenital heart disease. BMC Medical Genetics, 2009, 10, 113.	2.1	38
13	Abnormal Multimeric and Oligomeric Composition Is Associated With Enhanced Endothelial Expression of von Willebrand Factor in Pulmonary Hypertension. Chest, 1993, 104, 1455-1460.	0.8	34
14	Myocarditis in children and detection of viruses in myocardial tissue: Implications for immunosuppressive therapy. International Journal of Cardiology, 2011, 148, 204-208.	1.7	34
15	Circulating Platelet Aggregates Indicative of in Vivo Platelet Activation in Pulmonary Hypertension. Angiology, 1993, 44, 701-706.	1.8	32
16	Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thrombosis Research, 2010, 125, 38-43.	1.7	30
17	Endothelial Dysfunction Associated with Chronic Intravascular Coagulation in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 353-358.	1.7	28
18	Morphology of the Internal Elastic Lamina in Arteries from Pulmonary Hypertensive Patients: a Confocal Laser Microscopy Study. Modern Pathology, 2003, 16, 411-416.	5.5	28

#	Article	IF	Citations
19	Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation. Cardiology in the Young, 2005, 15, 26-30.	0.8	28
20	Differential Effects of Enzymatic Treatments on the Storage and Secretion of von Willebrand Factor by Human Endothelial Cells. Thrombosis Research, 2001, 101, 291-297.	1.7	24
21	Sleep in Infants with Congenital Heart Disease. Clinics, 2009, 64, 1205-1210.	1.5	24
22	Pulmonary Hypertension in Latin America. Chest, 2010, 137, 78S-84S.	0.8	23
23	Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. Brazilian Journal of Medical and Biological Research, 2011, 44, 1269-1275.	1.5	23
24	Frequency of 22q11.2 microdeletion in sporadic non-syndromic tetralogy of Fallot cases. International Journal of Cardiology, 2008, 126, 374-378.	1.7	22
25	Measurement, interpretation and use of hemodynamic parameters. Cardiology in the Young, 2009, 19, 8-12.	0.8	22
26	Lack of evidence of association between MTHFR C677T polymorphism and congenital heart disease in a TDT study design. International Journal of Cardiology, 2005, 105, 15-18.	1.7	21
27	The Impact of Preexisting Myocardial Remodeling onÂVentricular Function Early after Tetralogy of Fallot Repair. Journal of the American Society of Echocardiography, 2010, 23, 912-918.	2.8	21
28	Effect of Intentional Hemodilution on Platelet Survival in Secondary Pulmonary Hypertension. Chest, 1989, 95, 1207-1210.	0.8	19
29	Age-Dependent Likelihood of In Situ Thrombosis in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 217-223.	1.7	18
30	PrevalÃªncia e abordagem cirÃºrgica da estenose supravalvar pulmonar pÃ³s-operaÃ§Ã£o de jatene para transposiÃ§Ã£o das grandes artÃ©rias. Arquivos Brasileiros De Cardiologia, 2008, 91, 18-24.	0.8	14
31	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease. Annals of Thoracic Medicine, 2014, 9, 21.	1.8	13
32	Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 251-258.	1.7	12
33	Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome. Cardiology in the Young, 2005, 15, 504-513.	0.8	11
34	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Annals of Thoracic Medicine, 2014, 9, 1.	1.8	11
35	Relation of Cytokine Profile to Clinical and Hemodynamic Features in Young Patients With Congenital Heart Disease and Pulmonary Hypertension. American Journal of Cardiology, 2017, 119, 119-125.	1.6	11
36	Stimulation of Human Smooth Muscle Cell Proliferation by Thrombin Involves Increased Synthesis of Platelet-Derived Growth Factor. Chest, 1998, 114, 236-240.	0.8	10

#	Article	IF	Citations
37	PCR screening for 22q11.2 microdeletion: Development of a new cost-effective diagnostic tool. Clinica Chimica Acta, 2006, 369, 78-81.	1.1	10
38	Resultados do tratamento cirÃºrgico da coarctaÃ§Ã£o de aorta em adultos. Brazilian Journal of Cardiovascular Surgery, 2009, 24, 346-353.	0.6	10
39	Two Novel Antiâ€“von Willebrand Factor Monoclonal Antibodies. Thrombosis Research, 2000, 97, 3-13.	1.7	9
40	Can we start to think about consensus-oriented clinical practices?. Cardiology in the Young, 2009, 19, 1-3.	0.8	9
41	Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments. Pulmonary Circulation, 2019, 9, 1-13.	1.7	9
42	A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography. Brazilian Journal of Medical and Biological Research, 2002, 35, 1259-1263.	1.5	8
43	Increased Tyrosine Phosphorylation of Platelet Proteins Including pp125FAK Suggests Endogenous Activation and Aggregation in Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 411-415.	1.7	8
44	Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2006, 4, 53-59.	1.0	8
45	Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 175-183.	1.7	8
46	AusÃªncia de estreita associaÃ§Ã£o entre qualidade de vida e capacidade de exercÃcio na hipertensÃ£o arterial pulmonar. Arquivos Brasileiros De Cardiologia, 2012, 99, 876-885.	0.8	8
47	Capillary hemangiomatosis likeâ€lesions in lung biopsies from children with congenital heart defects. Pediatric Pulmonology, 2014, 49, E82-5.	2.0	8
48	Doppler flow evaluation can anticipate abnormal left lung perfusion after transcatheter closure of patent ductus arteriosus. European Heart Journal, 2004, 25, 1927-1933.	2.2	7
49	Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease. Clinics, 2013, 68, 531-536.	1.5	7
50	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulmonary Circulation, 2019, 9, 1-9.	1.7	7
51	Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. Congenital Heart Disease, 2019, 14, 246-255.	0.2	7
52	Atrial Septal Defect in Adults: Does Repair Always Mean Cure?. Arquivos Brasileiros De Cardiologia, 2014, 103, 446-8.	0.8	7
53	Aggregation of platelets in whole blood from children with pulmonary hypertension. International Journal of Cardiology, 1990, 28, 173-178.	1.7	6
54	Lung Î²-Adrenoceptors in Pulmonary Hypertension*. Chest, 1991, 99, 637-641.	0.8	6

#	Article	IF	Citations
55	Tratamento cirÃºrgico da persistÃªncia do canal arterial na populaÃ§Ã£o adulta. Brazilian Journal of Cardiovascular Surgery, 2011, 26, 93-97.	0.6	6
56	Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease. Brazilian Journal of Medical and Biological Research, 2013, 46, 375-381.	1.5	6
57	Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension. Thrombosis Research, 2016, 146, 15-19.	1.7	6
58	Factors influencing outcomes in patients with Eisenmenger syndrome: a nineâ€year followâ€up study. Pulmonary Circulation, 2017, 7, 635-642.	1.7	6
59	Relation of Macrophage Migration Inhibitory Factor to Pulmonary Hemodynamics and Vascular Structure and Carbamyl-Phosphate Synthetase I Genetic Variations in Pediatric Patients with Congenital Cardiac Shunts. Mediators of Inflammation, 2019, 2019, 1-10.	3.0	6
60	Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	5
61	Circulating blood volumes in pulmonary hypertension associated with erythrocytosis â€“ the effects of therapeutic hemodilution. Cardiology in the Young, 2003, 13, 544-550.	0.8	4
62	An immunohistochemical study of arterial lesions due to pulmonary hypertension in patients with congenital heart defects. Cardiology in the Young, 1994, 4, 37-43.	0.8	3
63	Causes of death and cardiovascular complications in adolescents and adults with congenitally malformed hearts: an autopsy study of 102 cases. Cardiology in the Young, 2009, 19, 511-516.	0.8	3
64	A computer-based matrix for rapid calculation of pulmonary hemodynamic parameters in congenital heart disease. Annals of Thoracic Medicine, 2009, 4, 124.	1.8	3
65	Is Surgical Treatment the Cure for Patients with Congenital Heart Disease?. Pulmonary Circulation, 2012, 2, 273-274.	1.7	3
66	Morphologic and immunohistochemical features of pulmonary vasculopathy in end-stage left ventricular systolic failure. Journal of Heart and Lung Transplantation, 2018, 37, 422-425.	0.6	3
67	Postoperative Pulmonary Hemodynamics and Systemic Inflammatory Response in Pediatric Patients Undergoing Surgery for Congenital Heart Defects. Mediators of Inflammation, 2022, 2022, 1-12.	3.0	3
68	Sialic acid content of von Willebrand factor subunit. Clinica Chimica Acta, 1998, 273, 209-211.	1.1	2
69	Congenital Heart Disease and Pulmonary Arterial Hypertension in South America (2013 Grover) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	2
70	Von Willebrand factor in severe pulmonary vascular obstructive disease â€” A structural and functional study in patients with schistosomiasis. Journal of Molecular and Cellular Cardiology, 1992, 24, 174.	1.9	1
71	Proteins C and S in Two Different Vaso-Occlusive Disorders. Acta Haematologica, 1993, 89, 54-55.	1.4	1
72	HipertensÃ£o arterial pulmonar hereditÃ¡ria apresentando-se como venopatia oclusiva. Arquivos Brasileiros De Cardiologia, 2011, 97, e8-e10.	0.8	1

#	Article	IF	Citations
73	Endothelial Alterations in Pulmonary Hypertension. , 2018, , 439-451.		1
74	Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: Relation to hemodynamic parameters and the presence of Down syndrome. Cytokine, 2020, 134, 155192.	3.2	1
75	When to Operate on Pediatric Patients with Congenital Heart Disease and Pulmonary Hypertension. Arquivos Brasileiros De Cardiologia, 2017, 109, 183-184.	0.8	1
76	A Rapid Method for the Detection of Alpha^{Iâ€™6}⁵ Hereditary Elliptocytosis. Acta Haematologica, 1993, 89, 52-53.	1.4	0
77	Orally Administered Acetylsalicylic Acid Decreases Protein Incorporation into the Cytoskeleton of Thrombin-Stimulated Platelets. Thrombosis Research, 1999, 95, 335-339.	1.7	0
78	Age and Method-dependent Variability of Predicted Oxygen Consumption in Congenital Heart Disease. Congenital Heart Disease, 2009, 4, 96-102.	0.2	0
79	2566 Likelihood of left main coronary artery compression in pulmonary hypertension based on the diameter of the pulmonary trunk. European Heart Journal, 2003, 24, 482.	2.2	0
80	P3381 Age-dependent risk of in situ thrombosis in secondary pulmonary hypertension. European Heart Journal, 2003, 24, 649.	2.2	0
81	P1152 Evaluation of pulmonary flow by Doppler echocardiography and scintigraphy after percutaneous closure of patent ductus arteriosus. European Heart Journal, 2003, 24, 213.	2.2	0
82	Pulmonary Hypertension Secondary to Congenital Systemic-to-Pulmonary (Left-to-Right) Shunts. , 2011, , 1139-1151.		0
83	Abstract 10210: Effects of Chronic Treatment With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil on Platelet Aggregation in Patients With Eisenmenger Syndrome. Circulation, 2015, 132, .	1.6	0